Navidea biopharmaceuticals, inc. receives nyse american notice

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it received a notice (the “notice”) on june 1, 2023 from the nyse american llc (the “nyse american”) stating that the company is not in compliance with the continued listing standards as set forth in section 1003(f)(v) of the nyse american company guide (“company.
NAVB Ratings Summary
NAVB Quant Ranking